Funding News Edition: November 06, 2019 See more articles in this edition
Apply for funds to better understand and evaluate bacteriophages and phage products used to prevent and treat bacterial infections. You could make new discoveries about how different phages interact with their bacterial hosts, in vivo phage distribution and pharmacokinetics, and other advances that will support rigorous assessments of clinical efficacy of phages.
Our funding opportunity announcement (FOA) Understanding Phage Biology To Support the Development of Bacteriophage Therapy (R21, Clinical Trial Not Allowed) supports studies to address key knowledge gaps that hinder further development and evidence-based regulation of phage-based products.
You must propose basic and/or translational research that could increase the overall knowledge base on therapeutic use of bacteriophage as products. The FOA lists many potential study ideas that would be appropriate. Here are the first few examples from each category:
- Basic research. Develop novel platforms, use synthetic biology and genetic engineering to improve or understand phage properties, or assess synergy between phages and antibiotics.
- Translational studies. Develop in vitro assays that predict in vivo efficacy, perform in vivo pharmacokinetic and distribution studies, or study efficacy with clinically relevant animal models.
Note that this FOA does not support Clinical Trial Research. NIAID offers other Opportunities if you wish to pursue preclinical or clinical development of phage and other non-traditional antibiotic products.
Budget and Award Details
You may request direct costs up to $275,000 total over two years. You cannot budget more than $200,000 in direct costs in any one year. NIAID plans to spend $2.5 million to fund six to eight awards in fiscal year 2021.
Apply by March 18, 2020.
If you have questions or would like to discuss your project ideas, contact Dr. Jane Knisely, the FOA’s scientific/research contact.